Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart rehab gets smarter: machine learning tailors exercise to your nerves

NCT ID NCT07288840

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to improve exercise prescription in cardiac rehabilitation by using machine learning to analyze data from the autonomic nervous system. Researchers will enroll 90 patients with coronary artery disease or non-ischemic heart failure. They will measure nerve activity and other biomarkers to create a personalized exercise plan, potentially making rehab safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized exercise prescription based on autonomic assessment
What this could lead to
If successful, this could lead to more effective and safer exercise plans for people in cardiac rehabilitation, improving heart health outcomes.
What could go wrong
This is a small, early-stage study focused on developing a method, not testing a treatment. The approach may not prove better than standard care or may be too complex for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with non-ischemic heart failure with reduced ejection fraction (NIHFrEF) or stable coronary artery disease without heart failure (CADnonHF), consecutively enrolled in the Cardiac Rehabilitation Program at Centro Hospitalar de Leiria, and undergoing comprehensive autonomic and metabolic assessment."

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with Coronary artery disease and no heart failure criteria * Patients with non ischaemic heart failure and reduced left ventricle ejection fraction Exclusion Criteria: * patients with ongoing acute coronary syndrome * patients with ongoing acute decompensated heart failure * Severe valvular heart disease that might confound the relationship between exercise and autonomic function. * Severe arrhythmias (e.g., sustained ventricular tachycardia, atrial fibrillation with a rapid ventricular rate) that are symptomatic or untreated * Severe uncontrolled hypertension (e.g., systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg) * Active infectious diseases or other significant acute medical illnesses (e.g., sepsis, active malignancy, acute kidney injury) * Pregnancy or lactation (to ensure safety during exercise interventions) * Significant cognitive impairment or mental illness (e.g., dementia, schizophrenia) that would impair the ability to follow exercise protocols or understand study instructions * nability to comply with study procedures due to any reason (e.g., language barriers, lack of informed consent) * Chronically immunocompromised states (e.g., HIV with CD4 count \< 200 cells/µL or on immunosuppressive therapy) * Presence of significant comorbidities such as advanced chronic obstructive pulmonary disease (COPD), kidney disease (e.g., stage 4-5 chronic kidney disease), or uncontrolled diabetes that would make exercise unsafe or confound the study outcomes * Critical limb ischemia, or severely symptomatic peripheral artery disease or claudication limiting functional capacity and response to exercise * Advanced chronic kidney disease (stage 4 or 5), due to contraindications with exercise * Severe anemia (hemoglobin \< 8 g/dL) or other blood disorders that affect exercise capacity * Inability to tolerate exercise due to other comorbidities or debility * individuals with known autonomic neuropathy (such as poorly controlled diabetes or neurodegenerative disorders) Specific Exclusion Criteria for Coronary Artery Disease (CAD) without Heart Failure Group: * Left ventricular ejection fraction (LVEF) \< 50% * Clinical/echocardiographic criteria of heart failure with oreserved ejection fraction. Specific Exclusion Criteria for Non-Ischemic Heart Failure with Reduced LVEF Group: * Ischemic heart disease or previous myocardial infarction * LVEF \> 40% * End-stage heart failure (e.g., patients on a heart transplant list, those with imminent need for mechanical circulatory support like LVAD). * Severe fluid overload that cannot be corrected

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic nervous system imbalance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ICVS - Life and Health Sciences Research Institute, Minho University Medical School

    Braga, Minho, 4710-057, Portugal

  • ciTechCare - Center for Innovative Care and Health Technology

    Leiria, Leiria District, 2414-016, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.